4.5 Article

Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau181P

Journal

NEUROCHEMISTRY INTERNATIONAL
Volume 55, Issue 4, Pages 214-218

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.neuint.2009.02.017

Keywords

Dementia; Alzheimer's disease; Cerebrospinal fluid; Biomarkers; Hyperphosphorylated tau

Ask authors/readers for more resources

To establish diagnostic accuracy (acc) and optimal cut-off levels of CSF tau phosphorylated at threonine 181 (P-tau(181P)) for discriminating Alzheimer's disease (AD) from non-AD dementias in autopsy-confirmed dementia patients, CSF levels of beta-amyloid peptide (A beta(1-42)). total tau protein (T-tau) and P-tau(181P) from patients with definite AD (n=95) and non-AD demential (n=50) were determined with single-parameter ELISA kits. Optimal P-tau(181P) cut-off levels for differentiating AD from pooled non-AD demential, dementia with Lewy bodies (DLB) and frontotemporal dementia (FTD) were 50.4 pg/mL (acc = 0.73), 52.8 pg/mL (acc = 0.73) and 35.3 pg/mL (acc = 0.90), respectively. The optimal CSF P-tau(181P) cut-off level for discriminating AD from non-AD demential was 50.4 pg/mL. Optimal CSF P-tau(181P) cut-off levels differed between non-AD diagnostic dementia categories. (C) 2009 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available